[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Icecure Medical Ltd Ord (ICCM)

Icecure Medical Ltd Ord (ICCM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,963
  • Shares Outstanding, K 2,807
  • Annual Sales, $ 3,380 K
  • Annual Income, $ -15,060 K
  • EBIT $ -4 M
  • EBITDA $ -4 M
  • 60-Month Beta 0.40
  • Price/Sales 1.77
  • Price/Cash Flow N/A
  • Price/Book 0.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.80
  • Number of Estimates 1
  • High Estimate $-1.80
  • Low Estimate $-1.80
  • Prior Year $-1.80
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.12 +139.62%
on 06/16/26
9.54 -46.75%
on 06/17/26
-1.52 (-23.03%)
since 05/18/26
3-Month
2.12 +139.62%
on 06/16/26
19.20 -73.54%
on 03/24/26
-12.92 (-71.78%)
since 03/18/26
52-Week
2.12 +139.62%
on 06/16/26
42.00 -87.91%
on 10/03/25
-23.42 (-82.18%)
since 06/18/25

Most Recent Stories

More News
IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

CAESAREA, Israel , June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...

ICCM : 5.27 (-17.66%)
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance

Increase driven by FDA clearance, clinical guideline support, and increased physician demand. Significant rise in number of leads for ProSense® systems generated at U.S. medical society conferences compared...

ICCM : 5.27 (-17.66%)
IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

Proactive Step to Regain Nasdaq Compliance as Part of the Company's Broader Capital Markets Strategy

ICCM : 5.27 (-17.66%)
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained recurrence-free...

ICCM : 5.27 (-17.66%)
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares

ICCM : 5.27 (-17.66%)
IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

Pent-up demand immediately following FDA clearance generates 46% increase in active customer accounts using ProSense® as of the end of the first quarter 2026, compared with prior to FDA clearance

ICCM : 5.27 (-17.66%)
IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

CAESAREA, Israel , May 6, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that...

ICCM : 5.27 (-17.66%)
IceCure Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market

As the only FDA cleared minimally invasive treatment option for low-risk breast cancer, ProSense® is aligned with the trend toward de-escalation of breast cancer treatment—a key theme at this year's...

ICCM : 5.27 (-17.66%)
IceCure Participates in Society of Breast Imaging Symposium 2026 as U.S. ProSense® Revenue Increases by 30%+ in First Quarter of 2026 Compared to First Quarter of 2025

The Company's participation at the Society of Breast Imaging Symposium and other upcoming medical conferences are timely as commercial momentum accelerates

ICCM : 5.27 (-17.66%)
IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

CAESAREA, Israel , March 26, 2026 /PRNewswire/ -- IceCure Medical Ltd . (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology...

ICCM : 5.27 (-17.66%)

Business Summary

IceCure Medical Ltd. develops and markets an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. IceCure Medical Ltd. is based in CAESAREA, Israel.

See More

Key Turning Points

3rd Resistance Point 15.37
2nd Resistance Point 12.45
1st Resistance Point 9.43
Last Price 5.27
1st Support Level 3.49
2nd Support Level 0.57
3rd Support Level N/A

See More

52-Week High 42.00
Fibonacci 61.8% 26.77
Fibonacci 50% 22.06
Fibonacci 38.2% 17.35
Last Price 5.27
52-Week Low 2.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.